Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
SKLN's Cash-to-Debt is ranked higher than
84% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. SKLN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SKLN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.23 Max: No Debt
Current: No Debt
Equity-to-Asset 0.73
SKLN's Equity-to-Asset is ranked lower than
81% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. SKLN: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
SKLN' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.72  Med: -4.26 Max: 0.73
Current: 0.73
-9.72
0.73
Interest Coverage No Debt
SKLN's Interest Coverage is ranked lower than
99.99% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. SKLN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SKLN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: -10.50
Beneish M-Score: -3.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1063.93
SKLN's Operating Margin % is ranked lower than
95% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. SKLN: -1063.93 )
Ranked among companies with meaningful Operating Margin % only.
SKLN' s Operating Margin % Range Over the Past 10 Years
Min: -18075  Med: -1907.48 Max: -679.31
Current: -1063.93
-18075
-679.31
Net Margin % -1063.93
SKLN's Net Margin % is ranked lower than
95% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. SKLN: -1063.93 )
Ranked among companies with meaningful Net Margin % only.
SKLN' s Net Margin % Range Over the Past 10 Years
Min: -18075  Med: -2009.83 Max: -717.86
Current: -1063.93
-18075
-717.86
ROE % -345.60
SKLN's ROE % is ranked lower than
99% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. SKLN: -345.60 )
Ranked among companies with meaningful ROE % only.
SKLN' s ROE % Range Over the Past 10 Years
Min: -345.6  Med: -259.12 Max: -259.12
Current: -345.6
-345.6
-259.12
ROA % -166.07
SKLN's ROA % is ranked lower than
98% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. SKLN: -166.07 )
Ranked among companies with meaningful ROA % only.
SKLN' s ROA % Range Over the Past 10 Years
Min: -1953.48  Med: -593.42 Max: -146.67
Current: -166.07
-1953.48
-146.67
ROC (Joel Greenblatt) % -1157.38
SKLN's ROC (Joel Greenblatt) % is ranked lower than
99% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. SKLN: -1157.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SKLN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -159177.78  Med: -13941.67 Max: -1157.38
Current: -1157.38
-159177.78
-1157.38
3-Year Revenue Growth Rate -69.60
SKLN's 3-Year Revenue Growth Rate is ranked lower than
99% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. SKLN: -69.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SKLN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37.9 Max: 16.9
Current: -69.6
0
16.9
3-Year EBITDA Growth Rate -72.20
SKLN's 3-Year EBITDA Growth Rate is ranked lower than
99% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. SKLN: -72.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SKLN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: -37.95 Max: -14.8
Current: -72.2
-72.2
-14.8
3-Year EPS without NRI Growth Rate -72.90
SKLN's 3-Year EPS without NRI Growth Rate is ranked lower than
96% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. SKLN: -72.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SKLN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -72.9  Med: -36.9 Max: -17.5
Current: -72.9
-72.9
-17.5
GuruFocus has detected 4 Warning Signs with Skyline Medical Inc $SKLN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SKLN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SKLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:UEEC, OTCPK:IGAP, NAS:AKER, OTCPK:VPTDF, OTCPK:STXS, OTCBB:NEPH, NAS:SSKN, OTCPK:REPR, OTCPK:REMI, OTCPK:PEYE, NAS:NURO, OTCPK:ECIA, OTCPK:RSCF, NAS:DXTR, OTCPK:UNISQ, OTCPK:SOAN, OTCPK:QTXB, OTCPK:ASNB, OTCPK:WHSI, OTCPK:GNID » details
Headquarter Location:USA
Skyline Medical Inc is a medical device company that manufactures and sells environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care.

Skyline Medical Inc, formerly known as BioDrain Medical Inc., was incorporated on April 23, 2002. The Company is a development stage medical device company manufacturing a system for the collection and disposal of infectious fluids that results from surgical procedures and post-operative care. The Company owns patent rights to products and distributes products to medical facilities where bodily and irrigation fluids produced during surgical procedures must be contained, measured, documented, and disposed. Its products minimize the exposure potential to the healthcare workers who handles such fluids. Its product, the STREAMWAY Fluid Management System, suctions surgical waste fluid from the patient using standard surgical tubing. The surgical waste fluid passes through disposable filters and into the STREAMWAY System. The STREAMWAY System maintains continuous suction to the surgical field. This simplifies the handling of fluids and will provide cost savings to facilities over the aggregate costs incurred using the traditional canister method of collection, neutralization and disposal. It sells its products through in-house sales force and intends to utilize independent distributors and manufacturer's representatives in the United States and Europe, initially, and eventually internationally. The Company competes with Cardinal Health, Inc. as well as Stryker Corporation, among others.

Top Ranked Articles about Skyline Medical Inc

Skyline Medical Reports 2017 First Quarter Financial Results
Skyline Medical to Hold Business Update Conference Call on May 16, 2017
Skyline Medical Reports 2016 Fourth Quarter and Full Year Financial Results and Provides Business Update

Conference call begins today at 4:30 p.m. Eastern time

MINNEAPOLIS, March 15, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), developer of the innovative STREAMWAY® waste fluid disposal system for medical applications, reports financial results for the three and 12 months ended December 31, 2016 and provides a business update.
Highlights of the fourth quarter of 2016 and recent weeks include: Awarded a contract to sell the STREAMWAY System to customers of Vizient, Inc., the largest member-driven health care performance improvement company in the countryReceived Vizient’s Innovative Technology designation that the STREAMWAY System offers unique and incremental benefits over other products available on the market todayAdded four regional sales managersRefined the STREAMWAY sales and marketing focus on the radiology marketplace, particularly on paracentesis and thoracentesis proceduresFurther migrated STREAMWAY marketing to a highly efficient electronic and digital strategySold four STREAMWAY Systems during the fourth quarter, bringing the total number of units installed to 100Received Health Canada medical device license to market and sell the STREAMWAY System in that countryRecorded the first sale of a STREAMWAY System in CanadaRaised more than $6.0 million during the fourth quarter and recent weeksAppointed Dr. Carl Schwartz as chief executive officerSecured shareholder approval for an increase in the number of authorized shares to 24 millionReceived notice from The Nasdaq Stock Market that the Company is in full compliance with all requirements for its stock’s continued listing on The Nasdaq Capital Market     Management Commentary “Skyline management and staff worked tirelessly during 2016 to set a viable business strategy and build a strong foundation for growth in 2017 and beyond.  I am delighted to report we are starting to see the positive results of our efforts, including the purchase by a top-ranked U.S. hospital of its fourth and fifth STREAMWAY Systems for its headquarters location during the fourth quarter,” said Dr. Schwartz. “We are grateful to our shareholders for voting affirmatively for some very difficult initiatives – a reverse stock split and two increases in authorized shares – that permitted us to raise growth capital while maintaining our Nasdaq listing.  These were vital actions to ensure Skyline’s viability and allow us to continue bringing the innovative and exceptional STREAMWAY System to patients and clinicians. “We expect to resume revenue growth in 2017 as we increase the size of our direct sales organization.  Our customer-acquisition activities are focused on radiology suites and include a heightened presence at radiology conferences.  As a result of these efforts, we are seeing a dramatic increase in the number of institutions seeking to trial the STREAMWAY System, which bodes very well for future sales.  Earlier this month we exhibited at the AHRA Association for Medical Imaging Management Spring Conference and garnered many excellent sales leads,” added Dr. Schwartz.  “Securing both the contract with Vizient and its Innovative Technology award are watershed events for Skyline.  The contract provides new avenues to reach member organizations as potential customers for STREAMWAY, and we are working with Vizient to finalize marketing materials. As a matter of perspective, we have been informed there are only 63 active Innovative Technology Contracts, and only one in four requests for contracts reaches agreement status, so we feel especially honored.” The Company provides an update on various sales and regulatory initiatives and agreements, as follows: Domestic sales.  We currently have an in-house dedicated U.S. sales group of five individuals, and affirm plans to add 25 to 30 commission-only independent reps by the end of the year.Marketing and sales in Canada.  Following Health Canada approval of STREAMWAY in November 2016, and upon further review of our strategy there, we have determined that direct sales via company and independent sales representatives will maximize the uptake of STREAMWAY.  We expect this approach will result in better control over the process, more trialing, faster sales decisions and improved economics to Skyline versus a distributor model. Canada represents a large market with approximately 10,000 operating rooms in approximately 1,500 hospitals across 13 provinces.CE Mark.  In late 2016 we contracted with TUV (a nationally recognized testing laboratory, or NRTL) to certify our STREAMWAY System to the new 60601-1 3rd Edition to conform to the European Union’s Medical Devices Directive.  This certification will be part of a technical file that will be submitted to our Notified Body (BSI) for recommendation for our CE Mark, which will allow us to sell STREAMWAY in European Union member states and certain other countries.  We expect this process to be completed in the next several weeks.GLG Pharma.  Our distribution arrangements with GLG Pharma for the UK, Poland and Central Europe are in place and rollout of the STREAMWAY System in those geographies is awaiting receipt of the CE Mark.  The diagnostic product we envisioned developing with GLG Pharma for use in conjunction with STREAMWAY is in the research and feasibility phase.Electronic On-Ramp (EOR) - negotiations are ongoing.    Munro Enterprises agreement.  Munro Enterprises, an Economically-Disadvantaged, Woman-Owned Small Business (EDWOSB), is working to distribute the STREAMWAY System to the U.S. federal government including U.S. Department of Veterans Affairs, U.S. Department of Defense and U.S. Health and Human Services facilities.  In its capacity as an EDWOSB, Munro is afforded special consideration to sell to these agencies. Financial Results Revenue for the fourth quarter of 2016 was $139,563 compared with $183,276 for the fourth quarter of 2015.  Revenue was derived from the sale of four STREAMWAY Systems and disposable products during each of these periods. Gross profit for the fourth quarter of 2016 was $107,074 or 76.7% of revenue, compared with $78,601 or 69.3% of revenue for the same period in 2015. Net loss available to common shareholders for the fourth quarter of 2016 was $732,772 or $0.16 per share, compared with a net loss available to common shareholders for the fourth quarter of 2015 of $2,263,006 or $10.87 per share. Weighted average shares used in calculation of loss per common share was 4,529,978 shares in the 2016 quarter and 208,257 shares in the 2015 quarter. For 2016 revenue was $456,000, compared with $654,000 in 2015.  Revenue in 2016 included the sale of four STREAMWAY systems and disposable supplies, and in 2015 included the sale of 20 STREAMWAY Systems and disposable supplies. Revenue declined in 2016 due to an insufficient sales force and limited brand awareness. The Company spent the first half of 2016 repositioning itself with its customer base and ensuring that its units were all the latest iteration. Gross profit for 2016 was $274,875 or 60.2% of revenue, compared with $350,372 or 53.5% of revenue for 2015.  In 2015 the Company absorbed the cost of upgrading or replacing earlier generation systems, which increased its cost of goods sold relevant to actual margin on new units sold.  In 2016 the Company completed those upgrades, which still reduced its margins but not as significantly.  Skyline expects 2017 to normalize to a higher gross profit margin. Net loss available to common shareholders for 2016 was $6,526,014 or $2.31 per share, compared with a net loss available to common shareholders for 2015 of $4,790,530 or $30.86 per share.  Weighted average shares used in the calculation of loss per share was 2,823,345 shares for 2016 and 155,233 shares for 2015. The Company had cash, cash equivalents and marketable securities of $2,148,419 as of December 31, 2016, compared with $4,856,232 as of December 31, 2015.  Subsequent to the close of the year, the Company raised gross proceeds of $4,295,812 in an underwritten public offering of stock and warrants. Conference Call Skyline Medical management will host a conference call beginning at 4:30 p.m. Eastern time today to discuss fourth quarter financial results, expectations for 2017 and to answer questions.  To access the conference call, please dial 844-666-7589 from within the U.S. or 443-961-0433 from outside the U.S. All listeners should provide passcode 86034782. Following the conclusion of the conference call, a telephone replay will be available through March 21, 2017 and can be accessed by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S.  All listeners should provide passcode 86034782.  About the STREAMWAY System Skyline's revolutionary, FDA-cleared STREAMWAY system is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.  As of December 31, 2016, Skyline Medical customers have installed 100 STREAMWAY systems in 50 facilities across 19 states. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855. About Skyline Medical
Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com. Forward-looking Statements
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable, adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov. SKYLINE MEDICAL INC.
BALANCE SHEETS     December 31,
2016  December 31,
2015 ASSETS        Current Assets:        Cash & cash equivalents $1,764,090  $4,856,232 Certificates of deposit  100,000   - Marketable securities  284,329   - Accounts Receivable  38,919   38,283 Inventories  272,208   231,740 Prepaid Expense and other assets  148,637   271,579 Total Current Assets  2,608,183   5,397,834          Fixed Assets, net  101,496   139,598 Intangibles, net  97,867   94,987          Total Assets $2,807,546  $5,632,419          LIABILITIES AND STOCKHOLDERS' EQUITY        Current Liabilities:        Accounts Payable $   220,112   $650,413 Accrued Expenses  1,346,105   864,295 Deferred Revenue  7,998   5,000 Total Current Liabilities  1,574,215   1,519,708          Accrued Expenses  309,649   - Total Liabilities  1,883,864   1,519,708 Commitments and Contingencies  -   - Stockholders’ Equity:        Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 1,895,010 outstanding  792   18,950 Common Stock, $.01 par value, 24,000,000 authorized, 4,564,428 and 208,258 outstanding  45,644   2,080 Additional paid-in capital  47,894,196   44,584,118 Accumulated deficit  (47,018,451)  (40,492,437)Accumulated Other Comprehensive Income  1,501   - Total Stockholders' Equity  923,682   4,112,711          Total Liabilities and Stockholders' Equity $2,807,546  $5,632,419 
SKYLINE MEDICAL INC.
STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Year Ended December 31,   2016  2015 Revenue $456,495  $654,354          Cost of goods sold  181,620   303,982          Gross margin  274,875   350,372          General and administrative expense  5,174,799   3,399,339          Operations expense  1,158,117   846,687          Sales and marketing expense  467,970   503,989          Interest expense  3   390,887          Total Expense  6,800,889   5,140,902          Net loss available to common shareholders  (6,526,014)  (4,790,530)         Other comprehensive income        Unrealized gain (loss) from marketable securities  1,501   -          Comprehensive loss $(6,524,513) $(4,790,530)         Loss per common share - basic and diluted $(2.31) $(30.86)         Weighted average shares used in computation - basic and diluted  2,823,345   155,233   

Contacts:
LHA
Kim Sutton Golodetz
[email protected]
212-838-3777
   or
Bruce Voss
[email protected]
310-691-7100

Read more...
Skyline Medical to Hold Business Update Conference Call on March 15, 2017

MINNEAPOLIS, March 09, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announced today that management will hold a conference call on March 15, 2017  to provide a business update and a discussion on recent and upcoming milestones.
The conference call is scheduled to begin at 4:30 p.m. (Eastern Time). To access the conference call, U.S.-based listeners should dial 844-666-7589 and international listeners should dial 443-961-0433. All listeners should provide the following passcode: 86034782. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at www.skylinemedical.com. Following the conclusion of the conference call, a replay will be available through March 21, 2017 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 86034782. The webcast will be available for 30 days. About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods — which require hand carrying and emptying filled fluid canisters — present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers, 2) improve compliance with OSHA and other regulatory agency safety guidelines, 3) improve efficiency in the operating room, and radiology and endoscopy departments — leading to greater profitability, and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United States. For additional information, please visit www.skylinemedical.com.
Contact:
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]

Read more...
Skyline Medical Awarded Innovative Technology Contract from Vizient, Inc. for STREAMWAY® System

MINNEAPOLIS, March 01, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”),producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal has received an Innovative Technology contract  from Vizient, Inc. With an annual purchasing volume of almost $100 billion, Vizient is the largest, member-driven health care performance improvement company in the country. The contract was based on a recommendation of STREAMWAY by hospital experts with expertise in this category who serve on one of Vizient’s member-led councils.  Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.
“We are delighted that STREAMWAY has been awarded the Innovative Technology contract, which will provide new avenues to reach member organizations as potential customers for STREAMWAY,” said Dr. Carl Schwartz, chief executive officer of Skyline Medical.  “We also are honored that the system has been recognized by Vizient for its innovation. The award is the culmination of more than a year’s work for Skyline, beginning with a presentation and subsequent participation in Vizient’s Summit.  The award has permitted STREAMWAY to be added to Vizient’s contracts outside of its competitive bidding cycle.” “Due to the number of products and services being released and marketed as ‘innovative’, member hospitals truly value the peer-review system in place at Vizient to help them identify products worth further evaluation at their own facilities,”  said Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program for suppliers.  “After a review of the STREAMWAY® System, Vizient’s member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation.” Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle. About the STREAMWAY System
Skyline's revolutionary, FDA-cleared STREAMWAY system is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.  As of September 30, 2016, Skyline Medical customers have installed 96 STREAMWAY systems in 50 facilities across 19 states. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855. About Skyline Medical
Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com. Forward-looking Statements
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable, adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology, including the possibility that the development of applicable technologies by GLG Pharma, LLC will be delayed, will not occur or will not receive applicable regulatory approvals on a timely basis; the Company's ability to consummate its joint venture with Electronic On-Ramp, Inc.; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.
Contact:
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.89
SKLN's PB Ratio is ranked lower than
88% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. SKLN: 2.89 )
Ranked among companies with meaningful PB Ratio only.
SKLN' s PB Ratio Range Over the Past 10 Years
Min: 1.36  Med: 4.22 Max: 1666.67
Current: 2.89
1.36
1666.67
PS Ratio 13.53
SKLN's PS Ratio is ranked lower than
83% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. SKLN: 13.53 )
Ranked among companies with meaningful PS Ratio only.
SKLN' s PS Ratio Range Over the Past 10 Years
Min: 1.05  Med: 21.32 Max: 5501.62
Current: 13.53
1.05
5501.62
EV-to-EBIT -1.56
SKLN's EV-to-EBIT is ranked lower than
99.99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. SKLN: -1.56 )
Ranked among companies with meaningful EV-to-EBIT only.
SKLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.6  Med: -2.3 Max: -0.1
Current: -1.56
-20.6
-0.1
EV-to-EBITDA -1.58
SKLN's EV-to-EBITDA is ranked lower than
99.99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. SKLN: -1.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
SKLN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.7  Med: -2.4 Max: -0.1
Current: -1.58
-20.7
-0.1
Current Ratio 4.05
SKLN's Current Ratio is ranked lower than
74% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. SKLN: 4.05 )
Ranked among companies with meaningful Current Ratio only.
SKLN' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: 4.05
Current: 4.05
0.01
4.05
Quick Ratio 3.86
SKLN's Quick Ratio is ranked lower than
60% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. SKLN: 3.86 )
Ranked among companies with meaningful Quick Ratio only.
SKLN' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.09 Max: 3.86
Current: 3.86
0.01
3.86
Days Inventory 751.57
SKLN's Days Inventory is ranked lower than
99% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. SKLN: 751.57 )
Ranked among companies with meaningful Days Inventory only.
SKLN' s Days Inventory Range Over the Past 10 Years
Min: 231.8  Med: 331.58 Max: 751.57
Current: 751.57
231.8
751.57
Days Sales Outstanding 47.07
SKLN's Days Sales Outstanding is ranked higher than
92% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. SKLN: 47.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
SKLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.21  Med: 75.65 Max: 365
Current: 47.07
21.21
365
Days Payable 218.45
SKLN's Days Payable is ranked higher than
99% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. SKLN: 218.45 )
Ranked among companies with meaningful Days Payable only.
SKLN' s Days Payable Range Over the Past 10 Years
Min: 218.45  Med: 2076.82 Max: 42444.29
Current: 218.45
218.45
42444.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -236.20
SKLN's 3-Year Average Share Buyback Ratio is ranked lower than
99% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. SKLN: -236.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SKLN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236.2  Med: -98.55 Max: -61.3
Current: -236.2
-236.2
-61.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 19.67
SKLN's Price-to-Net-Cash is ranked lower than
83% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. SKLN: 19.67 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SKLN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 6.46 Max: 70
Current: 19.67
0
70
Price-to-Net-Current-Asset-Value 3.05
SKLN's Price-to-Net-Current-Asset-Value is ranked lower than
69% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. SKLN: 3.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SKLN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 4 Max: 18.14
Current: 3.05
0
18.14
Price-to-Tangible-Book 2.95
SKLN's Price-to-Tangible-Book is ranked lower than
84% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. SKLN: 2.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SKLN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.8  Med: 3.86 Max: 15.47
Current: 2.95
2.8
15.47
Price-to-Median-PS-Value 0.63
SKLN's Price-to-Median-PS-Value is ranked higher than
88% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. SKLN: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SKLN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.04 Max: 51.45
Current: 0.63
0
51.45
Earnings Yield (Greenblatt) % -63.90
SKLN's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. SKLN: -63.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SKLN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -74.77  Med: 0 Max: 2601.9
Current: -63.9
-74.77
2601.9

More Statistics

Revenue (TTM) (Mil) $0.54
EPS (TTM) $ -1.27
Beta0.34
Short Percentage of Float21.77%
52-Week Range $1.52 - 6.75
Shares Outstanding (Mil)6.19

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)